<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368666</url>
  </required_header>
  <id_info>
    <org_study_id>TPS001</org_study_id>
    <nct_id>NCT01368666</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark</brief_title>
  <acronym>CAVALIER</acronym>
  <official_title>Perceval S Valve Clinical Trial for Extended CE Mark</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical investigation is to assess the safety and
      effectiveness of the Perceval S valve at 12 months after implantation when used to replace a
      diseased or dysfunctional aortic valve or aortic valve prosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoints

      The primary endpoint of the clinical investigation is the evaluation of the safety and
      effectiveness of the Perceval S valve at 12 months after implant.

      The safety of Perceval valve will be assessed in terms of percentage incidence of mortality
      and morbidity at 12 months after implant.

      The effectiveness of the Perceval s valve will be assessed in terms of:

        -  Improvement of clinical status by mean of New York Heart Association (NYHA) functional
           class at 12 months after implant

        -  Haemodynamic performance through echocardiography parameters as mean gradient and peak
           gradient, effective orifice area (EOA), effective orifice area indexed (EOAI),
           performance index, cardiac output, cardiac index and degree of regurgitation at 12
           months after implant

      In order to determine mortality and morbidity, the following specific device related and
      procedure related adverse event categories will be assessed:

      - valvular thrombosis, thromboembolism, hemorrhage (whether or not related to anti coagulant/
      antiplatelet drug therapy) [all and major], paravalvular leak (all and major), endocarditis,
      hemolysis, structural valve deterioration, non structural dysfunction, reoperation (all and
      valve related), explant, death (all and valve related), device dislodgement and device
      migration

      In order to assess the Haemodynamic performance the following echocardiography parameters
      will be measured:

      - mean gradient and peak gradient, effective orifice area (EOA), effective orifice area
      indexed (EOAI), performance index, cardiac output, cardiac index and degree of regurgitation

      Secondary Endpoints The secondary endpoints of the clinical investigation are:

        -  Assessment of mortality and morbidity rates at discharge (or 30 days if the patient is
           still hospitalized) and at 3-6 months after implant

        -  Evaluation of the effectiveness of Perceval S valve in terms of improvement of clinical
           status assessed by means of NYHA functional class at discharge (or 30 days if the
           patient is still hospitalized), 3-6 months after surgery

        -  Evaluation of the effectiveness of Perceval S valve in terms of haemodynamic performance
           through echocardiography at discharge (or 30 days if the patient is still hospitalized)
           and 3-6 months after surgery

        -  Mortality and morbidity as well as haemodynamic parameters will be assessed
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety and effectiveness</measure>
    <time_frame>12 months after OP</time_frame>
    <description>Incidence of mortality and morbidity. Effectiveness: NYHA functional class and haemodynamic performance.
Mortality and morbidity, adverse event categories: valvular thrombosis, thromboembolism, hemorrhage, paravalvular leak, endocarditis, hemolysis, SVD, non structural dysfunction, reoperation, explant, death, device dislodgement and device migration
Haemodynamic performance : mean gradient and peak gradient, EOA, EOAI, PI, cardiac output, cardiac index and degree of regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and effectiveness</measure>
    <time_frame>3-6 months</time_frame>
    <description>The secondary endpoints of the clinical investigation are:
Assessment of mortality and morbidity rates at discharge and at 3-6 months after OP
Evaluation of the valve effectiveness in terms of improvement of clinical status assessed by means of NYHA functional class at discharge, 3-6 months after OP
Evaluation of the effectiveness of Perceval S valve in terms of haemodynamic performance through echocardiography at discharge and 3-6 months after surgery
Mortality and morbidity as well as haemodynamic parameters will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">658</enrollment>
  <condition>Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Perceval S Valve Prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perceval S Valve Prosthesis</intervention_name>
    <description>Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis</description>
    <arm_group_label>Perceval S Valve Prosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of age &gt; 65 years;

          2. Subjects with aortic valve stenosis or steno-insufficiency;

          3. Subjects in which preoperative evaluation indicated the need for native or prosthetic
             aortic valve replacement with a biological prosthesis;

          4. Subjects willing to sign the informed consent;

          5. Subjects willing to undergo all medical follow-up, echocardiography examinations and
             laboratory tests planned for the Study

        Exclusion Criteria:

          1. Subjects involved in any other clinical study for drugs or devices;

          2. Subjects with a previously implanted Perceval S prosthesis, within the clinical study,
             that requires replacement

          3. Subjects with previous implantation of valve prostheses or annuloplasty ring not being
             replaced by the study valve

          4. Subjects requiring simultaneous cardiac procedures, apart from septal myectomy and/or
             coronary by-pass

          5. Subjects who require double or multiple valve replacement or repair in whom the
             mitral, tricuspid, or pulmonic valve would be replaced with a non-Perceval S valve or
             repaired

          6. Subjects with aneurysmal dilation or dissection of the ascending aortic wall

          7. Subjects needing non elective intervention

          8. Subjects with active endocarditis

          9. Subjects with active myocarditis

         10. Subjects with congenital bicuspid aortic valve

         11. Subjects with aortic root enlargement, where the ratio between the diameter of the
             sino-tubular junction and the annulus diameter, assessed by TTE, is &gt; 1.3 (see
             Attachment 1 for reference)

         12. Subjects with aortic root height (measured from aortic annulus to sino-tubular
             junction) ≥ 21 mm for size 21, ≥ 22.5 mm for size 23 and ≥ 24 mm for size 25, and ≥ 25
             mm for size XL/27

         13. Subjects with myocardial infarction &lt; 90 days before the planned valve implant surgery

         14. Subjects with known hypersensitivity to nickel alloys

         15. The subject has a documented history of substance (drug or alcohol) abuse

         16. The subject is a prison inmate, institutionalized, or is unable to give informed
             consent;

         17. The subject has a major or progressive non-cardiac disease that, in the investigator's
             experience, results in a life expectancy shorter than 1 year, or the implant of the
             device produces an unacceptable increased risk to the patient

         18. The subject is undergoing renal dialysis for chronic renal failure or has
             hyperparathyroidism

         19. The subject has had an acute preoperative neurological deficit, myocardial infarction,
             or cardiac event that has not returned to baseline or stabilized ≥ 30 days prior to
             the planned valve implant surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Haverich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Klinik für Chirurgie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Chirurgie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouw (OLV) Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique du Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefässzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHÖN Klinikum AG, Herz- und Gefäß-Klinik GmbH</name>
      <address>
        <city>Bad Neustadt/Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Süd</name>
      <address>
        <city>Nürnberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center, Division of Cardio-thoracic Surgery</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universitätsklinik für Herz- und Gefässchirurgie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genfield General Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE39QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>Biological valve</keyword>
  <keyword>Sutureless valve</keyword>
  <keyword>Stented valve</keyword>
  <keyword>Aortic Valve Disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

